JP2007508284A5 - - Google Patents

Claims (44)

Use of xenon in the preparation of a medicament for treating neonatal asphyxia in a subject neonate for use in combination with hypothermia therapy .   Use according to claim 1, characterized in that the xenon is mixed with a pharmaceutically acceptable diluent, excipient or carrier.   Use according to claim 1 or 2, characterized in that the medicament is gaseous.   4. Use according to claim 3, characterized in that the medicament is administered by inhalation.   Use according to any of claims 1 to 4, characterized in that xenon is administered in the form of a 20-70% v / v xenon-air mixture.   Use according to claim 1 or 2, characterized in that the xenon is administered by perfusion.   Use according to claim 1 or 2, characterized in that the medicament is in the form of a liquid or a solution.   8. Use according to claim 7, characterized in that the medicament is in the form of a fat emulsion.   Use according to claim 7 or 8, characterized in that the medicament is in a form suitable for intravenous, axonal or transdermal delivery.   Use according to any of claims 1 to 9, characterized in that the administration of xenon is performed simultaneously, sequentially or separately with hypothermia therapy.   Use according to claim 10, characterized in that the administration of xenon is performed simultaneously with hypothermia therapy.   The use according to any one of claims 1 to 11, wherein xenon is administered to a newborn mother who is the subject before giving birth.   Use according to claim 12, characterized in that xenon is administered to the mother of the newborn subject before or during labor.   14. Use according to claim 13, wherein the xenon is administered to the newborn mother of interest up to about 24 hours prior to childbirth.   15. Use according to any of claims 1 to 14, characterized in that hypothermia therapy is continued for at least about 6 hours after hypoxic ischemic (HI) injury.   16. Use according to any of claims 1 to 15, wherein the hypothermia is continued for about 6 to about 24 hours after hypoxic ischemic (HI) injury.   17. Use according to any of claims 1 to 16, characterized in that xenon is administered in a therapeutically effective amount.   17. Use according to any of claims 1 to 16, wherein xenon is administered in a therapeutically effective amount or less.   Use according to any of the preceding claims, wherein xenon is administered in combination with an anesthetic selected from isoflurane, sevoflurane and desflurane. A subject mammal is a newborn, body temperature of a mammal, Use according any one of claims 1 to 19, characterized in that it is maintained at about 32 ° C. ~ about 36 ° C.. 21. Use according to claim 20 , characterized in that the body temperature of the mammal is maintained at about 33C to about 35C.   Use of xenon in the preparation of a neonatal asphyxia treatment comprising the step of administering xenon to a subject simultaneously, sequentially or separately in combination with hypothermia therapy. A therapeutic agent for neonatal asphyxia in a mammal in need of neonatal asphyxia treatment , used in combination with hypothermia, comprising a therapeutically effective amount of xenon . 24. The drug according to claim 23 , wherein the mammal is a human. 25. A medicament according to claim 23 or 24 , comprising in addition to xenon, a pharmaceutically acceptable carrier, diluent and / or excipient. 26. A drug according to any one of claims 23 to 25 , wherein xenon is administered by inhalation. 27. A medicament according to claim 26, wherein the xenon is administered in the form of a 20-70% v / v xenon-air mixture. 26. The drug according to any one of claims 23 to 25 , wherein xenon is administered by perfusion. 26. A medicament according to any one of claims 23 to 25 , wherein xenon is administered in the form of a solution or an emulsion. 30. A medicament according to claim 29 , wherein xenon is administered in the form of a fat emulsion. 31. A drug according to claim 29 or 30 , wherein xenon is administered intravenously, axonally or transdermally. The drug according to any one of claims 23 to 31 , wherein the administration of xenon is performed simultaneously with the hypothermia therapy, sequentially, or separately. Administration of xenon, claim 32 of a drug, characterized in that it is performed simultaneously with hypothermia. 34. The medicament according to any one of claims 23 to 33, wherein the body temperature of the mammal is maintained at about 32C to about 36C . 35. The medicament according to claim 34 , wherein the body temperature of the mammal is maintained at about 33C to about 35C. 36. A medicament according to any of claims 23 to 35 , wherein hypothermia therapy is continued for at least 6 hours after hypoxic ischemic (HI) injury. 37. A medicament according to any of claims 23 to 36 , wherein hypothermia therapy is continued for about 6 to about 24 hours after hypoxic ischemic (HI) injury. 38. The medicine according to any one of claims 23 to 37 , wherein xenon is administered to a maternal mother before giving birth. 39. The medicament of claim 38 , wherein xenon is administered to a mammalian mother before or during labor. Xenon, the mother mammal claim 38 or 39 agents as defined and characterized in that it is administered up to about 24 hours prior to birth. 41. A medicament according to any one of claims 23 to 40 , wherein xenon is administered in a therapeutically effective amount. 41. A medicament according to any one of claims 23 to 40 , wherein xenon is administered in a therapeutically effective amount or less. 42. The medicament according to any one of claims 23 to 41 , wherein xenon is administered in combination with an anesthetic selected from isoflurane, sevoflurane and desflurane. A method of treating neonatal asphyxia in a mammal in need of treatment for neonatal asphyxia, medicament comprising the step of administering a therapeutically effective amount of xenon to the mammal in combination with hypothermia.